CClinicalTrials.gg
RecruitingNCT06707519Updated Apr 22, 2026

NSCLC Liquid Biopsies and Exhaled VOC

An observational study in Lung Cancer and Circulating Tumor DNA, sponsored by St. Joseph's Healthcare Hamilton. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by St. Joseph's Healthcare Hamilton · Observational

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for detecting mutations in extracted cell-free DNA in non-small cell lung cancer (NSCLC) patients, before and after surgery, and any recurrence within a 24-month postoperative follow-up period.

This is a pilot feasibility study, proposed as a 24-month prospective, single-center, non-interventional, observational trial with NSCLC-adenocarcinoma patients indicated for resection surgery with curative intent.

Read the detailed description

Circulating tumor DNA (ctDNA) is increased in patients with lung cancer, and may allow detecting minimal residual disease and disease recurrence, preceding radiological detection. Detecting ctDNA in bronchoalveolar lavage/Sputum was never validated and may offer advantages over blood ctDNA, and serve as a novel biomarker for lung cancer surveillance. Lung cancer detection is possible with eNose systems with a high negative predictive value and allows prediction of treatment response to PD1 inhibitors, monitoring response to PD1 inhibitors and predicting the presence of EGFR mutations. it is reasonable to anticipate exhaled VOC to aid in detection of cancer recurrence.

The study propulsion is patients undergoing surgical resection with curative intent for NSCLC, adenocarcinoma subtype at St. Joseph's Healthcare Hamilton and the Firestone Institute of Respiratory Health , above 18 years, able to provide consent. The study procedure is collecting blood, sputum, BAL samples, exhaled VOC will be collected at the following time-points/visits: (i) Visit 1 (V1): pre surgical resection; (ii) V2: immediately before discharge from hospital post-resection; (iii) V3,4,5 : 6, 12, 24 months post-surgery; (iv) V6: unscheduled at any sign of recurrence. to note, blood sputum and BAL will be collected at visit 1 and 2 from everyone and at visits 3-6 only from those who harbor a mutation of interest.

02

Conditions studied

  • Lung Cancer
  • Circulating Tumor DNA

Browse trials for

03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,558 are open to participants now.

This study's planned enrollment of 210 is above the median of 189 across 1,512 observational studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

St. Joseph's Healthcare Hamilton is the lead sponsor of 137 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing surgical resection with curative intent for NSCLC, adenocarcinoma subtype at St. Joseph's Healthcare Hamilton and the Firestone Institute of Respiratory Health , above 18 years, able to provide consent

Inclusion criteria

  • Patient must be at least 18 years of age
  • Patient must be able to provide consent
  • Patients undergoing surgical resection with curative intent for non-small cell lung cancer at St. Joseph's Healthcare Hamilton and Firestone Institute for Respiratory Health.

Exclusion criteria

Exclusion Criteria:

  • Resection done with non-curative intent or metastatic disease
  • other malignancies
  • Patients with previously treated malignancy less than 5 years prior to current resection (not including skin cancer).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Recruitment rate

    the proportion of eligible participants recruited (threshold \>75%)

    Time frame: December 2025

  2. Data completion rate

    proportion of samples that are usable (threshold \>80%)

    Time frame: December 2025

  3. Safety, adverse events

    any adverse events (threshold \<10%)

    Time frame: December 2025

07

Study locations

1 of 1 sites recruiting
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
    • Layla Halwagi, BSc · Contact · Lhalwagi@stjosham.on.ca · 905-522-1155
    • Yaron Shargall, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — There is currently no decision on whether the IPD will be available to other researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06707519
Lead sponsor
St. Joseph's Healthcare Hamilton
Responsible party
Yaron Shargall (Professor, St. Joseph's Healthcare Hamilton) — Principal investigator
First posted
Nov 27, 2024
Start date
Feb 1, 2023
Primary completion
Dec 29, 2027 (estimated)
Completion
Dec 29, 2027 (estimated)
Last update
Apr 22, 2026

Study contacts

Layla Halwagi, BSc
Contact
Lhalwagi@stjosham.on.ca
905-522-1155 ext. 31433

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion